Factors associated with clinical events (severe HPV infection excluded)
| Variables . | Crude IRR (95% CI)* . | P . | Adjusted IRR (95% CI)† . | P . |
|---|---|---|---|---|
| Donor origin | ||||
| Matched sibling | 1 | < .001 | 1 | .2 |
| Mismatched related | 3.7 (1.6-8.6) | 1.4 (0.6-3.4) | ||
| Pheno-related and unrelated | 4.8 (2.3-9.9) | 2.1 (0.9-5.4) | ||
| GVHD (acute) myeloid chimerism | 2.7 (1.8-4.0) | < .001 | 2.1 (1.3-3.2) | .002 |
| Mixed or donor origin | 1 | .03 | ||
| Recipient | 1.7 (1.0-2.8) | |||
| Molecular diagnosis | ||||
| RAG 1/2 | 1 | < .001 | 1 | .03 |
| Artemis | 6.0 (3.0-12) | 1.9 (0.8-4.5) | ||
| γc, JAK3, IL7Rα | 1.8 (0.9-3.5) | 0.9 (0.4-2.1) | ||
| Others | 1.5 (0.7-3.5) | 1.4 (0.5-3.5) | ||
| Immune reconstitution | ||||
| Low CD4+ T-cell counts | 2.7 (1.8-4.2) | < .001 | 1.8 (1.1-2.8) | .02 |
| Immunoglobulin substitution | 4.6 (2.9-7.2) | < .001 | 2.8 (1.5-5.3) | .002 |
| Variables . | Crude IRR (95% CI)* . | P . | Adjusted IRR (95% CI)† . | P . |
|---|---|---|---|---|
| Donor origin | ||||
| Matched sibling | 1 | < .001 | 1 | .2 |
| Mismatched related | 3.7 (1.6-8.6) | 1.4 (0.6-3.4) | ||
| Pheno-related and unrelated | 4.8 (2.3-9.9) | 2.1 (0.9-5.4) | ||
| GVHD (acute) myeloid chimerism | 2.7 (1.8-4.0) | < .001 | 2.1 (1.3-3.2) | .002 |
| Mixed or donor origin | 1 | .03 | ||
| Recipient | 1.7 (1.0-2.8) | |||
| Molecular diagnosis | ||||
| RAG 1/2 | 1 | < .001 | 1 | .03 |
| Artemis | 6.0 (3.0-12) | 1.9 (0.8-4.5) | ||
| γc, JAK3, IL7Rα | 1.8 (0.9-3.5) | 0.9 (0.4-2.1) | ||
| Others | 1.5 (0.7-3.5) | 1.4 (0.5-3.5) | ||
| Immune reconstitution | ||||
| Low CD4+ T-cell counts | 2.7 (1.8-4.2) | < .001 | 1.8 (1.1-2.8) | .02 |
| Immunoglobulin substitution | 4.6 (2.9-7.2) | < .001 | 2.8 (1.5-5.3) | .002 |
Because of strong colinearity between donor origin and occurrence of acute GHVD, 2 multivariate Poisson models were built (1 with donor origin, 1 with GVHD). Similarly, myeloid chimerism was not included in multivariate analysis because of colinearities. Negative factors in univariate analysis are not represented in the table (clinical condition and age at diagnosis, age at transplantation presence of maternofetal engraftment, use of conditioning regimen, degree of myeloablation [busulfan 8 or 16 mg/kg total dose]) and time of transplantation (before 1988, between 1989 and 1997, and after 1998).
IRR indicates incidence risk ratio.
Calculated by univariate survival analysis with a Poisson model.
Calculated by multivariate survival analysis with a Poisson model.